Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP5 | Q13451 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21001975 | 0.93 | — | — | |
| SCHEMBL8778459 | 0.76 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL9129408 | 0.75 | CRBN (0.40) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL1688444 | 0.74 | FKBP5 (0.36) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL11316947 | 0.73 | FKBP5 (0.39) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL6673999 | 0.73 | FKBP5 (0.39) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL23009712 | 0.71 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL11723152 | 0.71 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL466252 | 0.71 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL6118648 | 0.71 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4003907-A | Δ1 -1-Azacycloalkene-2-carboxylic acids and their production | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-18 | — | — | US | claimed |
| US-9840515-B2 | Protein kinase D inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840515-B2 | Protein kinase D inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840515-B2 | Protein kinase D inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-12 | — | — | US | disclosed |
| US-20140045821-A1 | PROTEIN KINASE D INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2014-02-13 | — | — | US | disclosed |
| US-20140045821-A1 | PROTEIN KINASE D INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2014-02-13 | — | — | US | disclosed |
| US-20140045821-A1 | PROTEIN KINASE D INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2014-02-13 | — | — | US | disclosed |
| WO-2012078859-A2 | PROTEIN KINASE D INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-06-14 | — | — | WO | disclosed |
| US-7414078-B2 | Oral general anesthetics and metabolitically resistant anticonvulsants | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414078-B2 | Oral general anesthetics and metabolitically resistant anticonvulsants | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-08-19 | — | — | US | disclosed |
| EP-0267277-B1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED LACTAMS | WHITBY RESEARCH INC (US) | 1994-01-19 | — | — | EP | disclosed |
| EP-0267277-A4 | COMPOSITIONS COMPRISING 1-SUBSTITUTED LACTAMS. | NELSON RES & DEV COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| US-4755535-A | Compositions comprising 1-substituted azacycloalkenes | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1988-07-05 | — | — | US | disclosed |
| EP-0267277-A1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED LACTAMS. | NELSON RES & DEV (US) | 1988-05-18 | — | — | EP | disclosed |
| WO-1987006583-A1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED LACTAMS | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1987-11-05 | — | — | WO | disclosed |
| US-4520021-A | ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1985-05-28 | — | — | US | disclosed |
| US-4409146-A | Substituted caprolactam derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-10-11 | — | — | US | disclosed |
| EP-0049505-A2 | Substituted caprolactam derivatives, a process for preparing and a pharmaceutical composition containing the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| US-4003907-A | Δ1 -1-Azacycloalkene-2-carboxylic acids and their production | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045821-A1 | PROTEIN KINASE D INHIBITORS | PRKCD, PRKD1, PRKD2 | FKBP5 1624/4885CRBN 3341/4885GRIN1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.